Trial Profile

A Phase I Dose-Escalation and Phase II Study of Nanobody-Based CD19/CD22 Tandem Dual Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 15 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti CD19/CD22 chimeric antigen receptor T cell therapy Hebei Senlang Biotechnology (Primary) ; Cyclophosphamide; Fludarabine
Indications B-cell leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Therapeutic Use
Acronyms Phase I/II

30 Mar 2026 Planned number of patients changed from 30 to 50.
30 Mar 2026 Planned End Date changed from 31 Dec 2026 to 31 Dec 2028.
30 Mar 2026 Planned primary completion date changed from 31 Dec 2025 to 31 Dec 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com